71 related articles for article (PubMed ID: 37326491)
1. Brief Communication: Lambert-Eaton Myasthenic Paraneoplastic Syndrome Associated With Merkel Cell Carcinoma Successfully Treated by Immune Checkpoint Inhibitors: 2 Cases.
Gra M; Pham-Ledard A; Gerard E; Dutriaux C; Beylot-Barry M; Duval F; Carla L; Soulages A; Prey S
J Immunother; 2023 Sep; 46(7):276-278. PubMed ID: 37326491
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome.
Machiyama H; Minami S
J Med Cases; 2023 Feb; 14(2):71-75. PubMed ID: 36896371
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic Lambert-Eaton myasthenic syndrome: a diagnostic challenge.
Viveiros L; Martins SR; Pires SX; Neves J
BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36707096
[TBL] [Abstract][Full Text] [Related]
4. Unusual paraneoplastic syndromes in pancreatic cancer: a case report of Lambert-Eaton myasthenic syndrome (LEMS) associated with intraductal papillary mucinous cancer of the pancreas.
Zamparas A; Herzog T; Förster S; Siglienti I; Uhl W; Strotmann J; Höhn P
AME Case Rep; 2023; 7():35. PubMed ID: 37942046
[TBL] [Abstract][Full Text] [Related]
5. Paraneoplastic neurologic manifestations of neuroendocrine tumors.
Zoccarato M; Grisold W
Handb Clin Neurol; 2024; 200():397-407. PubMed ID: 38494292
[TBL] [Abstract][Full Text] [Related]
6. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Stege HM; Haist M; Schultheis S; Fleischer MI; Mohr P; Ugurel S; Terheyden P; Thiem A; Kiecker F; Leiter U; Becker JC; Meissner M; Kleeman J; Pföhler C; Hassel J; Grabbe S; Loquai C
Cancer Immunol Immunother; 2021 Nov; 70(11):3313-3322. PubMed ID: 33870464
[TBL] [Abstract][Full Text] [Related]
7. Regionally Metastatic Merkel Cell Carcinoma Associated with Paraneoplastic Anti-
Shalhout SZ; Emerick KS; Sadow PM; Linnoila JJ; Miller DM
Case Rep Oncol Med; 2020; 2020():1257587. PubMed ID: 33062358
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of durvalumab plus chemotherapy in small-cell lung cancer with Lambert-Eaton myasthenic syndrome.
Ishibashi N; Tabata T; Nonomura R; Oshima Y; Sasaki T; Mitomo H; Sugawara T; Sagawa M
Respir Med Case Rep; 2024; 47():101974. PubMed ID: 38374927
[TBL] [Abstract][Full Text] [Related]
9. [A 50 year old man with progressive weakness in lower limbs].
Thors B; Gudmundsson B
Laeknabladid; 2023 Nov; 109(11):508-512. PubMed ID: 37909447
[TBL] [Abstract][Full Text] [Related]
10. A Rare Case of Lambert-Eaton Myasthenia Syndrome Associated with Non-Hodgkin's Lymphoma: A Case Report and Review of the Literature.
Abu-Tineh M; Alamin MA; Aljaloudi E; Alshurafa A; Garcia-Cañibano B; Taha RY; Elkourashy SA
Case Rep Oncol; 2023; 16(1):1300-1305. PubMed ID: 37942405
[TBL] [Abstract][Full Text] [Related]
11. [Peripheral Neuropathy and Muscle Disorders as Immune-Related Adverse Events].
Suzuki S
Brain Nerve; 2024 May; 76(5):605-611. PubMed ID: 38741503
[TBL] [Abstract][Full Text] [Related]
12. Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer.
Agrawal K; Agrawal N
Case Rep Neurol Med; 2019; 2019():5353202. PubMed ID: 31355029
[TBL] [Abstract][Full Text] [Related]
13. Overview of treatment strategies in paraneoplastic neurological syndromes.
Kerstens J; Titulaer MJ
Handb Clin Neurol; 2024; 200():97-112. PubMed ID: 38494299
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced Lambert-Eaton myasthenic syndrome: an immune-related adverse event in nonsmall cell lung cancer.
Rehman ST; Azeem SM; Akbar A; Shafiq O; Azeem SS; Ali SHA
J Chemother; 2023 Oct; ():1-5. PubMed ID: 37837370
[TBL] [Abstract][Full Text] [Related]
15. Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors.
Jean MJ; Samkoff L; Mohile N
Curr Treat Options Oncol; 2024 Jan; 25(1):42-65. PubMed ID: 38198120
[TBL] [Abstract][Full Text] [Related]
16. Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma.
Tachiki LML; Hippe DS; Williams Silva K; Hall ET; McCamy W; Fritzsche D; Perdue A; Majovski J; Pulliam T; Goldstein DA; Veatch J; Ho J; Nghiem PT; Thompson JA; Bhatia S
Cancer Immunol Immunother; 2023 Nov; 72(11):3839-3850. PubMed ID: 37733060
[TBL] [Abstract][Full Text] [Related]
17. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes.
Farina A; Villagrán-García M; Vogrig A; Zekeridou A; Muñiz-Castrillo S; Velasco R; Guidon AC; Joubert B; Honnorat J
Lancet Neurol; 2024 Jan; 23(1):81-94. PubMed ID: 38101905
[TBL] [Abstract][Full Text] [Related]
18. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
Vilaseca A; Farina A; Villagrán-García M; Pegat A; Benaiteau M; Ciano-Petersen NL; Do LD; Rogemond V; Gonçalves D; Psimaras D; Birzu C; Honnorat J; Joubert B
J Neurol; 2024 Mar; ():. PubMed ID: 38467790
[TBL] [Abstract][Full Text] [Related]
19. Neuronal Antibodies and Associated Syndromes.
Arneth BM
Autoimmune Dis; 2019; 2019():2135423. PubMed ID: 31380113
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review.
Xiong G; Young RB; Chow H; Maverakis E; Maselli RA; Richman DP; Li T
Front Oncol; 2023; 13():1199195. PubMed ID: 37465116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
